首页> Annals of translational medicine> Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma.

Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Nana,Ping

第一单位： Department of Hematology, the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.;Institute of Blood and Marrow Transplantation, Suzhou, China.;Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

作者： Nana,Ping ^[1] ; Changju,Qu ^[1] ; Mengyun,Li ^[1] ; Liqing,Kang ^[2] ; Danqin,Kong ^[1] ; Xiaochen,Chen ^[1] ; Qian,Wu ^[1] ; Fan,Xia ^[3] ; Lei,Yu ^[2] ; Hong,Yao ^[4] ; Lingzhi,Yan ^[1] ; Depei,Wu ^[1] ; Zhengming,Jin ^[1]

作者单位： Department of Hematology, the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.;Institute of Blood and Marrow Transplantation, Suzhou, China.;Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. ^[1] Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd., Shanghai, China.;School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China. ^[2] Department of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou, China. ^[3] Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China. ^[4]

关键词 Refractory/relapsed (R/R)chimeric antigen receptor T cell (CAR-T)diffuse large B-cell lymphoma (DLBCL)lenalidomide

DOI 10.21037/atm-22-20

PMID 35433994

发布时间 2022-07-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Annals of translational medicine

2022年10卷6期

298页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览2

点击下载本期目录封面

Annals of translational medicine

2022年10卷6期

298页

检索历史清除

Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma.

Annals of translational medicine

相似文献

同项目论文

Annals of translational medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma.

Annals of translational medicine

相似文献

同项目论文

Annals of translational medicine

相关期刊

检索历史清除